Nitric oxide for the prevention and treatment of viral, bacterial, protozoal and fungal infections [version 1; peer review: 1 approved with reservations]

Bath, Philip M.; Coleman, Christopher M; Gordon, Adam L.; Lim, Wei Shen; Webb, Andrew J

Abstract

Although the antimicrobial potential of nitric oxide (NO) is widely published, it is little used clinically. NO is a key signalling molecule modulating vascular, neuronal, inflammatory and immune responses. Endogenous antimicrobial activity is largely mediated by high local NO concentrations produced by cellular inducible nitric oxide synthase, and by derivative reactive nitrogen oxide species including peroxynitrite and S-nitrosothiols. NO may be taken as dietary substrate (inorganic nitrate, L-arginine), and therapeutically as gaseous NO, and transdermal, sublingual, oral, intranasal and intravenous nitrite or nitrate. Numerous preclinical studies have demonstrated that NO has generic static and cidal activities against viruses (including β-coronaviruses such as SARS-CoV-2), bacteria, protozoa and fungi/yeasts in vitro. Therapeutic effects have been seen in animal models in vivo, and phase II trials have demonstrated that NO donors can reduce microbial infection. Nevertheless, excess NO, as occurs in septic shock, is associated with increased morbidity and mortality. In view of the dose-dependent positive and negative effects of NO, safety and efficacy trials of NO and its donors are needed for assessing their role in the prevention and treatment of infections. Trials should test dietary inorganic nitrate for pre- or post-exposure prophylaxis and gaseous NO or oral, topical or intravenous nitrite and nitrate for treatment of mild-to-severe infections, including due to SARS-CoV-2 (COVID-19). This review summarises the evidence base from in vitro, in vivo and early phase clinical studies of NO activity in viral, bacterial, protozoal and fungal infections.

Citation

Bath, P. M., Coleman, C. M., Gordon, A. L., Lim, W. S., & Webb, A. J. (2021). Nitric oxide for the prevention and treatment of viral, bacterial, protozoal and fungal infections [version 1; peer review: 1 approved with reservations]. F1000Research, 10, 1-34. https://doi.org/10.12688/f1000research.51270.1

• Journal Article Type: Article
• Acceptance Date: Jun 21, 2021
• Online Publication Date: Jul 5, 2021
• Publication Date: Jul 5, 2021
• Deposit Date: Jun 21, 2021
• Publicly Available Date: Jul 5, 2021
• Journal: F1000Research
• Electronic ISSN: 2046-1402
• Publisher: F1000 Research Ltd
• Peer Reviewed: Peer Reviewed
• Volume: 10
• Article Number: 536
• Pages: 1-34
• DOI: https://doi.org/10.12688/f1000research.51270.1
• Public URL: https://nottingham-repository.worktribe.com/output/5717963
• Publisher URL: https://f1000research.com/articles/10-536/v1